Meloxicam | The Contraceptive Pipeline Database

Product Overview

Development Status: Inactive

Target: Female

Mode: Non-hormonal

Delivery Type: Oral

Duration Type: Emergency

Description: A non-hormonal emergency contraceptive option. It is a cyclooxygenase-2 (COX-2) inhibitor that blocks ovulation. Dosing is 30 mg for 5 days. Meloxicam is marketed as a nonsteroidal, anti-inflammatory agent used for pain.

Updated date: May 30, 2018

Vertical Tabs

Product Details

Active Pharmaceutical Ingredient (API): meloxicam

Potential Multi-Purpose Technology (MPT): No

Regimen: Taken after unprotected intercourse for 5 days

Duration: 5 days

Dose: 30 mg (per day)

Partner: CONRAD

Status

Project Phase: Late Development

Project Stage: Phase II

Status Details:
A Phase II trial (led by CONRAD) in Santiago, Chile tested the safety and efficacy of 2 different doses of meloxicam, 15 mg and 30 mg, taken daily for 5 days for the prevention of ovulation. Findings indicate that the 30 mg dose is safe and effective and may offer an alternative to hormonal emergency contraception.

Programmatic Considerations

Considerations:
Meloxicam may have a broader window of effectiveness and fewer side effects than current emergency contraceptive methods.

COX-2 inhibitors are accessible over-the-counter in many countries. Potential to also use as a form of monthly oral contraceptive.

Additional Information

Additional Information:
McCann NC, et al. (2013) The COX-2 inhibitor meloxicam prevents pregnancy when administered as an emergency contraceptive to nonhuman primates. Contraception. 88(6):744-8.

Download Product Report